Skip to main content

Clinical Studies on Cytokine-Induced Killer Cells: Lessons from Lymphoma Trials.

Cancers

Authors: Ying Zhang, Amit Sharma, Hans Weiher, Matthias Schmid, Glen Kristiansen, Ingo G H Schmidt-Wolf

Cancer is a complex disease where resistance to therapies and relapses often pose a serious clinical challenge. The scenario is even more complicated when the cancer type itself is heterogeneous in nature, e.g., lymphoma, a cancer of the lymphocytes which constitutes more than 70 different subtypes. Indeed, the treatment options continue to expand in lymphomas. Herein, we provide insights into lymphoma-specific clinical trials based on cytokine-induced killer (CIK) cell therapy and other pre-clinical lymphoma models where CIK cells have been used along with other synergetic tumor-targeting immune modules to improve their therapeutic potential. From a broader perspective, we will highlight that CIK cell therapy has potential, and in this rapidly evolving landscape of cancer therapies its optimization (as a personalized therapeutic approach) will be beneficial in lymphomas.

PMID: 34885117

Participating cluster members